ArticleClinicoEconomics and outcomes research : CEOR2025
A Method for Adjusting EQ-5D-3L Health State Utilities for Cross-Country Use: Application of a Novel US-to-UK Utility Mapping Approach.
Article in ClinicoEconomics and outcomes research : CEOR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The EuroQoL-five dimensions-three levels (EQ-5D-3L) utility values vary across regions, hence become non-interchangeable. This study details a methodology to adjust EQ-5D-3L utility values from the published United States (US) scores for use in the United Kingdom (UK) when individual-level patient data (IPD) are inaccessible. Methods: Linear and polynomial regression models were fitted to map the US-derived EQ-5D-3L health state utility weights (HSUWs) into UK values. Model fit was evaluated via visual inspection and coefficient of determination ( Results: The linear model confirmed linearity between US and UK HSUWs, and was the best-fit over the polynomial model, both visually and with Conclusion: A robust method was developed to adjust US-derived EQ-5D-3L utilities and reflect UK preferences. This method helps predict and transpose utilities from the literature across countries as a supporting tool when IPD are unavailable, which is necessary when adapting cost-effectiveness models to different settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.